Xiao‐Dong Zhu

ORCID: 0000-0002-8982-3411
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Head and Neck Cancer Studies
  • Head and Neck Surgical Oncology
  • Lung Cancer Treatments and Mutations
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Lung Cancer Research Studies
  • Advanced Radiotherapy Techniques
  • Brain Metastases and Treatment
  • Lung Cancer Diagnosis and Treatment
  • Cancer-related molecular mechanisms research
  • Esophageal Cancer Research and Treatment
  • Gastrointestinal Tumor Research and Treatment
  • Gastric Cancer Management and Outcomes
  • Cancer-related cognitive impairment studies
  • Cancer survivorship and care
  • Oral health in cancer treatment
  • Breast Cancer Treatment Studies
  • Ear and Head Tumors
  • Cardiac Valve Diseases and Treatments
  • Prostate Cancer Treatment and Research
  • Aortic Disease and Treatment Approaches
  • Cancer Diagnosis and Treatment
  • Salivary Gland Disorders and Functions
  • Salivary Gland Tumors Diagnosis and Treatment
  • Cardiac and Coronary Surgery Techniques
  • Mechanical Circulatory Support Devices

Guangxi Medical University
2014-2025

Fudan University Shanghai Cancer Center
2022-2025

Tumor Hospital of Guangxi Medical University
2016-2025

Shanghai Medical College of Fudan University
2022

Weatherford College
2019-2021

Tongren Hospital
2020

Shanghai Jiao Tong University
2020

Creative Commons
2019

Nanning Normal University
2016

Chinese Academy of Medical Sciences & Peking Union Medical College
2012-2014

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based primary point, may be published when key planned co-primary or secondary analyses are not yet available. Trial Updates provide an opportunity to disseminate additional results from studies, in JCO elsewhere, for which point has already been reported.We previously reported significantly improved failure-free survival using gemcitabine plus cisplatin induction...

10.1200/jco.22.00327 article EN Journal of Clinical Oncology 2022-06-16

Importance Approximately 20% to 30% of patients with locoregionally advanced nasopharyngeal carcinoma (NPC) experience disease relapse despite definitive chemoradiotherapy. The programmed cell death 1 (PD-1) blockade camrelizumab has demonstrated considerable value in recurrent or metastatic NPC, while its role NPC is unclear. Objective To evaluate the efficacy and safety adjuvant for NPC. Design, Setting, Participants Randomized, open-label, multicenter, phase 3 clinical trial conducted...

10.1001/jama.2025.1132 article EN other-oa JAMA 2025-03-13

Abstract Background There is no consensus on whether triplet regimen better than doublet in the first‐line treatment of advanced gastric cancer (AGC). We aimed to compare efficacy and safety oxaliplatin plus capecitabine (XELOX) epirubicin, oxaliplatin, (EOX) regimens treating AGC. Methods This phase III trial enrolled previously untreated patients with AGC who were randomly assigned receive XELOX or EOX regimen. The primary endpoint was non‐inferiority progression‐free survival (PFS) for as...

10.1002/cac2.12278 article EN Cancer Communications 2022-02-25

Abstract BACKGROUND The purpose of the current study was to evaluate tolerance and efficacy hypofractionated three‐dimensional conformal radiotherapy (3DCRT) with or without transarterial chemoembolization (TACE) for technically unresectable medically inoperable primary liver carcinoma (PLC). METHODS Between April 1999 August 2003, 128 patients a clinical diagnosis PLC received 3DCRT at Cancer Hospital, Guangxi Medical University. Both TACE were used treat 48 these patients. Liver cirrhosis...

10.1002/cncr.21012 article EN Cancer 2005-04-05

Radioresistance remains one of the important factors in relapse and metastasis nasopharyngeal carcinoma. Thus, it is imperative to identify genes involved radioresistance explore underlying biological processes development radioresistance. In this study, we used cDNA microarrays select differential between radioresistant CNE-2R parental CNE-2 cell lines. One hundred eighty-three significantly differentially expressed (p<0.05) were identified, which 138 upregulated 45 downregulated CNE-2R. We...

10.3892/ijo.2011.1172 article EN International Journal of Oncology 2011-08-19

The aim of this study was to prospectively evaluate the cognitive function, depression, anxiety, and sleep quality in patients with nasopharyngeal cancer (NPC) before after intensity-modulated radiotherapy (IMRT).Eligible newly diagnosed NPC treated primary IMRT were recruited. A series neuropsychological tests performed within 1 week IMRT. Cognitive function measured Das-Naglieri assessment system. Self-rating Anxiety Scale Depression used assess mood states. Sleep evaluated by means...

10.1002/pon.3542 article EN Psycho-Oncology 2014-04-11

335 Background: Blocking TGF-β signaling has the potential to facilitate recovery from chemo-induced myelosuppression. SHR-1701 is a bifunctional agent targeting PD-L1 and TGF-β. Methods: In multicenter, randomized, double-blind phase 3 study (NCT04950322), plus CAPOX demonstrated statistically significant clinically meaningful benefit in OS compared with placebo patients (pts) previously untreated, unresectable locally advanced or metastatic HER2-negative G/GEJA (ESMO 2024, LBA60). Here, we...

10.1200/jco.2025.43.4_suppl.335 article EN Journal of Clinical Oncology 2025-01-27

Objective. To evaluate the efficacy and safety of Kangfuxin Solution, a pure Chinese herbal medicine, on mucositis induced by chemoradiotherapy in nasopharyngeal carcinoma patients. Methods. A randomized, parallel-group, multicenter clinical study was performed. total 240 patients were randomized to receive either Solution (test group) or compound borax gargle (control during chemoradiotherapy. Oral mucositis, upper gastrointestinal oral pain evaluated Common Terminology Criteria for Adverse...

10.1155/2016/8692343 article EN cc-by Evidence-based Complementary and Alternative Medicine 2016-01-01

461 Background: For unresectable locally advanced or metastatic HER2-negative gastric cancer (GC), the combination of chemotherapy with immunotherapy, specifically PD-1 inhibitors, has emerged as a new standard care in first-line treatment GC, but patients’ outcomes remain poor. Early clinical studies investigating immunotherapy anti-angiogenic drugs have demonstrated favorable efficacy. Therefore, it is worth exploring whether addition fruquintinib, potent VEGFR-1,2,3 inhibitor, to...

10.1200/jco.2025.43.4_suppl.461 article EN Journal of Clinical Oncology 2025-01-27

Patients with synchronous metastatic nasopharyngeal carcinoma (smNPC) exhibit significant heterogeneity, and clinical prognostic models suitable for this cohort remain limited. We aimed to develop a prediction tool facilitate personalised assessments inform treatment decisions these patients. This retrospective multicentre study enrolled 556 patients smNPC. The training comprised 386 from Guangxi Medical University Cancer Hospital, while the external validation 170 Wuzhou Red Cross Hospital...

10.1186/s13014-025-02602-1 article EN cc-by-nc-nd Radiation Oncology 2025-03-20

// Kai-Hua Chen 1 , Xiao-Dong Zhu 1,2,3 Ling Li Song Qu Zhen-Qiang Liang Xia Xin-Bin Pan Zhong-Guo and Yan-Ming Jiang Department of Radiation Oncology, Affiliated Tumor Hospital Guangxi Medical University, Cancer Institute Zhuang Autonomous Region, Nanning, Guangxi, China 2 Key Laboratory Early Prevention Treatment for Regional High Frequency (Guangxi University), Ministry Education, 3 Correspondence to: Zhu, email: Keywords : nasopharyngeal neoplasm, stage II, concurrent chemoradiotherapy,...

10.18632/oncotarget.11978 article EN Oncotarget 2016-09-12

The purpose of this study was to compare the quality life (QoL) stage II nasopharyngeal carcinoma (NPC) patients treated with radiotherapy (RT) versus concurrent chemoradiotherapy (CCRT). In a cross-sectional study, these were RT (n = 55) or CCRT 51) between June 2008 and 2013. For all subjects, disease-free survival more than 3 years. QoL assessed using European Organization for Research Treatment Cancer Quality Life Questionnaire-Core 30 (EORTC QLQ-C30) questions Head Neck 35 QLQ-H&N35)...

10.18632/oncotarget.14932 article EN Oncotarget 2017-02-01

We compared treatment outcomes in patients with stage II nasopharyngeal carcinoma (NPC) treated intensity-modulated radiotherapy (IMRT) or two-dimensional conventional (2D-CRT). Stage (2010 UICC/AJCC staging system) NPC IMRT (n = 178) 2D-CRT 73) between January 2007 and December 2014 were retrospectively analyzed. Patients matched using the propensity score-matching method. The primary endpoint was overall survival (OS). Secondary endpoints local relapse-free (LRFS), regional (RRFS), distant...

10.18632/oncotarget.17481 article EN Oncotarget 2017-04-27

Abstract: Due to the smaller size, artificial surface, and higher efficiency, axial blood pumps have been widely applied in clinic recent years. However, because of its high rotor speed, flow pump always has a risk for hemolysis, which red cells devastated by shearing tip clearance flow. We reported novel design with integrated blade‐shroud structure that was expected solve this problem abolishing radial between blade casing designed techniques computational fluid dynamics (CFD). numerical...

10.1111/j.1525-1594.2007.00425.x article EN Artificial Organs 2007-05-26

Two-dimensional conventional radiotherapy (2D-CRT) and intensity-modulated (IMRT) are effective for control of nasopharyngeal carcinoma (NPC). The purpose this study was to compare the quality life (QoL) stage II NPC patients treated with 2D-CRT versus IMRT. We conducted a cross-sectional 106 (n = 47) IMRT 59) between June 2008 2013. For all subjects, disease-free survival more than 3 years. QoL assessed using European Organization Research Treatment Cancer Quality Life Questionnaire-Core 30...

10.18632/oncotarget.17582 article EN Oncotarget 2017-05-03

To identify predictors for improvement of xerostomia in patients with nasopharyngeal carcinoma (NPC) treated intensity-modulated radiotherapy (IMRT).Patients diagnosed stage I-IVb NPC (according to the 7th edition American Joint Committee on Cancer) between September 2015 and March 2016 were retrospectively analyzed. All received IMRT. Predictors analyzed using logistic regression analysis. Receiver operating characteristic curve analysis was used most appropriate cut-off values predicting...

10.1097/md.0000000000017030 article EN cc-by-nc Medicine 2019-09-01

Although common, the use of chemotherapy for stage II nasopharyngeal carcinoma (NPC) is controversial due to its undefined clinical benefits. We therefore conducted a retrospective cohort study investigate whether confers survival gains NPC patients. A total 251 (2010 UICC/AJCC staging system) patients treated between January 2007 and December 2014 were retrospectively analyzed. Patients matched using propensity-score matching method. The primary endpoint was overall (OS). Secondary...

10.18632/oncotarget.21751 article EN Oncotarget 2017-10-11

BACKGROUND:To compare the effects of chemotherapy dose escalation on survival and prognosis nasopharyngeal carcinoma (NPC) patients who developed bone-only metastasis. MATERIAL AND METHODS:Between October 2000 to March 2017, 58 NPC with initial metastasis were retrospectively analyzed. Patients received <6 or ≥6 cycles matched grouped using receiver operating characteristic curve (ROC) analysis. Overall (OS) was assessed Kaplan-Meier method, log-rank test, Cox regression RESULTS:The median...

10.12659/msm.922244 article EN Medical Science Monitor 2020-06-15
Coming Soon ...